What is HC Wainwright’s Forecast for Liquidia Q2 Earnings?

Liquidia Corporation (NASDAQ:LQDA) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for Liquidia in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.86 per share for the quarter, up from their previous estimate of $0.49. HC Wainwright currently has a “Buy” rating and a $67.00 target price on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.14 per share. HC Wainwright also issued estimates for Liquidia’s Q3 2026 earnings at $1.15 EPS, Q4 2026 earnings at $1.43 EPS, FY2026 earnings at $3.97 EPS, FY2027 earnings at $5.94 EPS and FY2029 earnings at $6.40 EPS.

Several other equities research analysts also recently weighed in on LQDA. Oppenheimer increased their target price on shares of Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research note on Thursday, March 12th. Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. BTIG Research increased their target price on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Liquidia Trading Up 1.7%

Shares of LQDA opened at $57.59 on Thursday. Liquidia has a twelve month low of $11.85 and a twelve month high of $57.80. The company has a market cap of $5.12 billion, a P/E ratio of 411.39 and a beta of 0.41. The company has a current ratio of 2.22, a quick ratio of 1.84 and a debt-to-equity ratio of 1.18. The company’s fifty day simple moving average is $38.70 and its 200-day simple moving average is $35.54.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The company’s quarterly revenue was up 4187.1% on a year-over-year basis.

Insiders Place Their Bets

In other Liquidia news, CFO Michael Kaseta sold 139,390 shares of the stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60. Following the transaction, the chief financial officer directly owned 353,356 shares in the company, valued at $14,183,709.84. This represents a 28.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 318,893 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the transaction, the director owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. The trade was a 14.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 972,713 shares of company stock worth $41,856,503 in the last three months. Corporate insiders own 25.60% of the company’s stock.

Institutional Trading of Liquidia

Several hedge funds have recently modified their holdings of LQDA. Federated Hermes Inc. purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $7,290,000. Caprock Group LLC acquired a new position in Liquidia in the 3rd quarter worth approximately $37,114,000. Farallon Capital Management LLC increased its holdings in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the period. Apis Capital Advisors LLC acquired a new position in Liquidia in the 3rd quarter worth approximately $9,569,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Liquidia in the 3rd quarter worth approximately $2,026,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported Q1 results that topped expectations on both earnings and revenue, reinforcing the company’s commercialization progress and improving profitability. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and outlined at least $1 billion in net revenue by 2027, which supports the stock’s growth narrative. YUTREPIA sales and 2027 revenue target
• Positive Sentiment: Several analysts turned more bullish after earnings, with firms including Needham, BTIG, and Wells Fargo raising price targets or reaffirming favorable ratings. Analyst price target updates
• Positive Sentiment: LQDA was added to Zacks’ Rank #1 Strong Buy list, adding momentum-driven support for the shares. Zacks Strong Buy list
• Neutral Sentiment: CEO Roger Jeffs and Director Stephen Bloch disclosed insider stock sales. The CEO’s sale was made under a pre-arranged 10b5-1 plan, while Bloch’s larger sale may still attract investor attention but does not necessarily signal a business deterioration. SEC filing
• Negative Sentiment: One recent research note suggested YUTREPIA’s launch momentum could be nearing a ceiling, which may raise questions about how long the current growth rate can persist. Rating downgrade article

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).